1
00:00:00,000 --> 00:00:05,875
Comparing medicines is more informative when they are tested within the same trial.

2
00:00:05,875 --> 00:00:10,542
SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity.

3
00:00:10,542 --> 00:00:17,208
The 2025 randomized study enrolled 751 participants without type two diabetes and followed treatment for

4
00:00:17,208 --> 00:00:21,458
72 weeks. Participants and researchers knew the assigned medicine.

5
00:00:21,458 --> 00:00:28,125
Tirzepatide produced a larger average reduction in body weight and waist circumference under the tested

6
00:00:28,125 --> 00:00:32,375
conditions. Gastrointestinal adverse events were common in both groups.

7
00:00:32,375 --> 00:00:35,875
This comparison answers a specific weight-management question.

8
00:00:35,875 --> 00:00:43,333
It does not identify the best choice for every person or compare every formulation, health outcome, or

9
00:00:43,333 --> 00:00:46,833
long-term risk.